AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04152720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured.
Study NCT01017640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: Daily for 12 months
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Daily for 12 months
Study NCT00104572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Cardone 500mg with vitamin D 400 IU
Description: 1 tablet three times a day
Study NCT00104572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Cardone 500mg with vitamin D 400 IU
Description: 1 tablet three times a day
Study NCT01017640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00005089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
Study NCT02934464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAMUCIRUMAB
Study NCT00795288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group
Study NCT04451473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS )
Description: the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
Study NCT04451473 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )
Description: the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
Study NCT03233035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
Study NCT03233035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Study NCT01181258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
Study NCT00703092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiber-Stat
Description: Liquid fiber supplement, 2 tablespoons twice daily.
Study NCT01181258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
Study NCT01181258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
Study NCT01181258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
Study NCT01181258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
Study NCT01181258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
Study NCT03522831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
Study NCT03522831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
Study NCT01075984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Posaconazole
Study NCT01075984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Study NCT01075984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Study NCT01075984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Study NCT01510899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single dose of RO4917838
Study NCT02532985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: No added fiber beverage
Study NCT02532985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Fiber Control
Description: positive control fiber supplemented beverage provided over 4 servings
Study NCT02532985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided over 4 servings
Study NCT03323190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient COPD education
Study NCT01120990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure Measurement
Description: All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
Study NCT01577147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ovulation predictions products
Description: Home diagnostics for ovulation prediction will be provided to study volunteers
Study NCT06332846 — intervention group
Intervention type: OTHER
Intervention: oral examination
Description: The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
Study NCT06332846 — intervention group
Intervention type: OTHER
Intervention: oral examination
Description: The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
Study NCT02494427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM manufactured fixed unitary dental prostheses
Study NCT02494427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally manufactured unitary dental prostheses
Study NCT00602147 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood or cheek cells wil be collected.
Study NCT04796376 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: combined partial fistulectomy or fistulotomy and cutting seton procedure
Description: Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
Study NCT02258126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention program
Description: Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months.
Study NCT02258126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Description: Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months.
Study NCT02276729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Box Therapy
Description: Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
Study NCT03348345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Breathe Thrive
Description: Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
Study NCT00005089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Study NCT02004028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6063
Study NCT02773927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in tablet presentation of 500 mg
Study NCT02773927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin in tablet presentation of 500 mg
Study NCT02773927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Agave inulin
Description: Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
Study NCT02773927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave inulin
Description: Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
Study NCT02773927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder
Study NCT02773927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder
Study NCT02773927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study NCT02773927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study NCT04999150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-Osteoperforations
Description: MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)
Study NCT04999150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticotomy
Description: A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)
Study NCT03986320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeogo™ Dermoskeleton
Description: This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Study NCT00278954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gammaplex (Intravenous immunoglobulin)
Description: GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
Study NCT02930551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02930551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Study NCT03410420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole hydrochloride
Description: administration of pimonidazole-HCl
Study NCT03410420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimonidazole hydrochloride
Description: administration of pimonidazole-HCl
Study NCT05020067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: superficial parotid lobe-sparing intensity-modulated radiotherapy
Description: The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
Study NCT04476524 — intervention group
Intervention type: OTHER
Intervention: Quality improvement
Description: All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
Study NCT00807079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00807079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00929526 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liquid-based cytology (LBC) sampling
Description: LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
Study NCT00929526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) sampling
Description: LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
Study NCT00929526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected at Months 36 and 48 for antibody determination
Study NCT03305705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Single intravenous infusion within 20 min
Study NCT00005089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Study NCT00005089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
Study NCT00005089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
Study NCT00005089 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
Study NCT04436406 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [99mTc]-NM-01 SPECT/CT
Description: Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
Study NCT01731600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
Study NCT04252560 — intervention group
Intervention type: PROCEDURE
Intervention: Colectomy, CRS+HIPEC
Description: No special interventions are going to be performed. Fecal samples are going to be taken and analysed
Study NCT01329822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction
Study NCT01201291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normobaric oxygen
Description: Fraction of inspired oxygen
Study NCT03348644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphate tablets.
Study NCT03348644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High cheese intake.
Study NCT03348644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High milk intake.
Study NCT02918136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived regenerative cells
Study NCT02918136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injectable
Study NCT04539444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/22 CART
Description: CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
Study NCT04539444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive Tislelizumab 200mg/dose every 3 weeks.
Study NCT04555993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower abdominal surgery
Description: Patients will undergo lower abdominal surgery under general anesthesia.
Study NCT04555993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower abdominal surgery
Description: Patients will undergo lower abdominal surgery under general anesthesia.
Study NCT04555993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
Study NCT04555993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
Study NCT01359813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin
Description: Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
Study NCT01903096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
Study NCT01903096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Treatment As Usual
Description: Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
Study NCT01679964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir switch
Description: Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
Study NCT02934464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel
Study NCT02934464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 4
Study NCT02934464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX 6
Study NCT03305705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9%
Description: Single intravenous infusion of 250 ml within 20 min
Study NCT01000207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Description: High dose group and low dose group of adjuvanted vaccines
Study NCT02556268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose
Study NCT01840098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low leucine content drink
Study NCT01840098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high leucine content drink
Study NCT01840098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low leucine + HMB drink